Nestlé Health Science Collaborate with Aimmune on Food Allergy Project

636141924688079833allergens.jpg

08 Nov 2016 --- Nestlé Health Science has announced that it will make an equity investment of $145 million in US-based Aimmune Therapeutics, to accelerate the development of technology designed to desensitize people with food allergies, protecting them from the consequences of accidental exposure.

Up to 250 million people globally are estimated to suffer from food allergies, between 5-8% of who children and 1-2% of adults.

Amongst the top eight food allergies, peanut allergy, which is generally a lifelong condition, is estimated to impact 6 million people in the US and in Europe or between 0.6 and 1.3% of the population in the US.

Aimmune’s Characterized Oral Desensitization ImmunoTherapy approach to treating life-threatening food allergies is based on extensive independent scientific research.

It demonstrates that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular, food, through the oral administration of gradually increasing amounts of the allergens.

It aims to provide a transformative treatment option that goes beyond the current standard of care of avoiding food allergens and carrying epinephrine for administration in case of accidental exposure.

Greg Behar, CEO of Nestlé Health Science, who will take a seat on the Aimmune Board, stated: “Food allergies have a huge personal impact and are a health economic burden.”

“We are investing and innovating to change the approach to food allergy management with integrated approaches from diagnostics to nutrition solutions and now biologics, where Aimmune’s proprietary approach has transformational potential in lives of patients and families.”

Aimmune’s lead Characterized Oral Desensitization ImmunoTherapy product candidate, AR101 for peanut allergy, is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts designed to desensitize patients with peanut allergy.

The ongoing Phase III trial, conducted by Aimmune, is expected to deliver results in 4Q2017, which – if positive – may support the filing of marketing authorization in the US and Europe.

Stephen Dilly, CEO of Aimmune, said, “Nestlé Health Science is an ideal partner that brings a shared vision, global scale and complementary capabilities to this collaboration, making the whole more than the sum of the parts.”

“We are excited to have Nestlé Health Science alongside as we pursue our development plans and seek to realize the full promise of our CODIT approach by addressing the important questions in food allergy around optimizing treatments, achieving sustained unresponsiveness, and exploring the science around tolerance.”

Having already established a portfolio of nutritional solutions for pediatric food allergy and intolerances, the investment extends Nestlé Health Science’s interests in the food allergy arena.  

The strategic investment launches a two-year strategic collaboration between the two companies, the terms of which enable the parties to engage on Aimmune’s current and future oral immunotherapy development programs through a newly established pipeline forum.

Nestlé Health Science will provide ongoing scientific, regulatory and commercial expertise and advice to Aimmune through the pipeline forum, and in addition, has a three-month exclusive right of first negotiation for any development program in the event Aimmune considers licensing or partnering such a program.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

UK yogurt sugar content often well above recommended threshold, survey finds

21 Sep 2018 --- Many yogurts sold in UK supermarkets contain high levels of sugar, a survey published in BMJ has highlighted. Researchers from the Universities of Leeds and Surrey analyzed the product information of 921 yogurts and found that organic yogurts and those marketed towards children, in particular, had high levels of sugar. Fewer than 9 percent of products surveyed contained less than the 5 g of sugar per 100 grams threshold required to be classed “low sugar” and carry a green “traffic light” nutritional label in the UK. As such, reformulation for the reduction of free sugars in yogurts is warranted.

Health & Nutrition News

High gluten diet during pregnancy could double risk of diabetes in children, study finds

20 Sep 2018 --- A high gluten intake by mothers during pregnancy may be associated with an increased risk of their child developing Type 1 diabetes, a study published in The BMJ suggests.

Health & Nutrition News

Adapting to the market? Adaptogens thrive on natural and health trends, but marketing remains a challenge

20 Sep 2018 --- Products that are clean label, natural and have health benefits are in vogue, and busy lifestyles are putting a spotlight on foods and beverages that can offer some stress relief and mood balancing effects. It’s no wonder then that adaptogens – claimed to stabilize physiological processes and promote homeostasis – are having a moment. Featured in a growing number of product categories, suppliers tip ongoing research into their capabilities as well as consumer education as necessary for continued growth.

Packaging & Technology News

Nutritional and environmental impacts: Premier Protein delivers on consumer demands

19 Sep 2018 --- Premier Protein shakes will now feature FSC-certified – meaning the materials used have been responsibly sourced – Tetra Pak cartons and a re-sealable plant-based cap derived from sugarcane. Consumers are ever more mindful when it comes to making purchasing decisions, both in terms of personal nutrition and environmental footprint. Premier Protein – a line of shakes, powders, bars and clear drinks – has launched its new Earth First packaging for its ready-to-drink shakes, hoping to attract sustainability-seeking consumers. 

Health & Nutrition News

ASEAN health and wellness boom spurs Australian innovation potential: CSIRO and KPMG

18 Sep 2018 --- The ASEAN region’s growth prospects and market conditions, coupled with an increased interest in health & wellness, have created a fertile ground for Australian food innovators and companies to do business in the region, according to a report by Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO) and professional service company KPMG.

More Articles
URL : http://www.nutritioninsight.com:80/news/nestl%C3%A9-health-science-collaborate-with-aimmune-on-food-allergy-project.html